Top Markets
Coin of the day
Biostar Pharmaceuticals, Inc. Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc.

BSPM
Rang in Aktien #42724
Biostar Pharmaceuticals, Inc. develops, manufactures, and markets... Biostar Pharmaceuticals, Inc. develops, manufactures, and markets pharmaceutical products for various diseases and conditions in the People's Republic of China. The company principally offers Xin Ao Xing Oleanolic Acid capsule, an OTC medicine for chronic hepatitis B. It also provides OTC products, such as Ganwang compound paracetamol and amantadine hydrochloride capsule for the relief of common cold, runny nose, sore throat, headache, and fever; Tianqi Dysmenorrhea capsule, a traditional Chinese medicine used for pain and other symptoms associated with menstruation; Deafness Tongqiao pills for hepatobiliary Huosheng, head swelling, deafness and tinnitus, ear pus, dry stool, and urine-yellow; Wenweishu capsules for the treatment of chronic gastritis and pain of epigastric cold; Zhitongtougu ointment for treating joint pain, swelling, tenderness, or dysfunction; and Chuzhang Zehaifu tablets for cataract. In addition, the company provides prescription pharmaceutical products, including Danshen granules; Taohuasan pediatric medicines; Jingang tablets; Danxiang Rhinitis tablets; Yanlixiao capsules; Piracetam tablets; Huangyangning tablets; Hyperthyroidism capsules; Fosfomycin Calcium capsules; Qianlietong capsules; Yituo Erythromycin particles; Danshen tablets; Muxiang Shunqi pills; Sifangwei capsules; and Aspirin Enteric-coated tablets. It sells its products through distributors and website that serves as internet-based China Hepatitis Internet Hospital, which offers HBV patients with information on HBV and treatment options, as well as methods to purchase HBV medicines. The company was incorporated in 2007 and is headquartered in Xianyang, the People's Republic of China.
Aktienkurs
$0.0001
Zuletzt synchronisiert: 2026-08-11
Marktkapitalisierung
$264.00
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
CN
Handel Biostar Pharmaceuticals, Inc. (BSPM)

Kategorie

P/B-Verhältnis für Biostar Pharmaceuticals, Inc. (BSPM)
P/B-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Biostar Pharmaceuticals, Inc. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/B-Verhältnis bei 0.
P/B-Verlauf für Biostar Pharmaceuticals, Inc. von 2026 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber